Sign in Subscribe
COVID-19

Increasing Incidence and Prevalence of Inflammatory Bowel Disease in Colombia

Strategic Insights

— 2 min read

A recent study published in Gastroenterologia y Hepatologia has shed light on the rising incidence and prevalence of inflammatory bowel disease (IBD) in Colombia, including Crohn's disease (CD) and ulcerative colitis (UC). The research, conducted by Hospital Pablo Tobon Uribe, analyzed real-world data from the national claims database SISPRO between 2017 and 2021. The study found that the incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals between 2017 and 2019, while the incidence for CD rose from 0.48 to 0.83 per 100,000. The prevalence of these conditions reached its highest point in 2019, with UC at 48.65 and CD at 15.41 per 100,000 population.

Key Takeaways:

  • The incidence and prevalence of IBD, including CD and UC, have increased across Latin America, with a significant impact on patients' quality of life and healthcare resource utilization.
  • The study analyzed 54,961 cases of prevalent UC and 13,136 cases of CD, with mortality data indicating 259 deaths registered with UC and 77 with CD.
  • The utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed.
  • The patterns observed in outpatient visits and hospital admissions followed similar trajectories, exhibiting a downturn during the COVID-19 pandemic.
  • The study emphasizes the need for informed decision-making and resource allocation for enhanced patient care in Colombia.
  • The research highlights the importance of using real-world data from national claims databases to understand the epidemiology and healthcare resource utilization of IBD.
  • The study's findings could contribute to the development of more effective treatment strategies and policies in Colombia and other Latin American countries.

Statistics:

  • Incidence rates for UC increased from 3.82 to 5.18 per 100,000 individuals between 2017 and 2019.
  • Incidence rates for CD rose from 0.48 to 0.83 per 100,000 between 2017 and 2019.
  • Prevalence of UC reached its highest point in 2019 at 48.65 per 100,000 population.
  • Prevalence of CD reached its highest point in 2019 at 15.41 per 100,000 population.
  • Mortality data indicated 259 deaths registered with UC and 77 with CD.
  • Utilization of biologic therapies saw a significant rise from 2020 to 2021, particularly with anti-TNF agents being the most frequently prescribed.

Sources:

  • Hospital Pablo Tobon Uribe
  • Gastroenterologia y Hepatologia (Elsevier Espana Slu, Av Josep Tarradellas, 20-30, 1ERA Planta, Barcelona, Cp-08029, Spain)
  • NewsRx LLC (www.newsrx.com)

Read more